Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of RA.~* All subjects will be required to have been taking a stable dose of methotrexate.~* Active RA at screening defined as greater than or equal to 6 swollen joints.~* The presence of erosive disease~Exclusion Criteria:~* Received any biologic agent (e.g., Enbrel®, Remicade®, Humira®, Kineret®) or Arava® within 8 weeks before randomization; past use of these agents is allowed.~* Steroid use greater than 15 mg/day.~* Scheduled for surgery or joint replacement in the hands, wrists or feet.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab 180 mg (Type: EXPERIMENTAL): Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
- Denosumab 60 mg (Type: EXPERIMENTAL): Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injections on Day 1 and at Month 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).